NovoCure Limited (NVCR)
18.51
0.74 (4.16%)
At close: Apr 24, 2025, 3:59 PM
19.22
3.83%
After-hours: Apr 24, 2025, 07:36 PM EDT
4.16% (1D)
| Bid | 17.4 |
| Market Cap | 2.06B |
| Revenue (ttm) | 605.22M |
| Net Income (ttm) | -168.63M |
| EPS (ttm) | -1.56 |
| PE Ratio (ttm) | -11.87 |
| Forward PE | -7.94 |
| Analyst | Buy |
| Ask | 21.04 |
| Volume | 1,167,975 |
| Avg. Volume (20D) | 875,675 |
| Open | 18.75 |
| Previous Close | 17.77 |
| Day's Range | 17.40 - 19.25 |
| 52-Week Range | 11.88 - 34.13 |
| Beta | 0.65 |
About NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed c...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date Oct 1, 2015
Employees 1,488
Stock Exchange NASDAQ
Ticker Symbol NVCR
Website https://www.novocure.com
Analyst Forecast
According to 6 analyst ratings, the average rating for NVCR stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 72.88% from the latest price.
Stock ForecastsEarnings Surprise
NovoCure has released their quartely earnings
on Apr 24, 2025:
Next Earnings Release
NovoCure Limited is scheduled to release its earnings on Apr 24, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-12.43%
NovoCure shares are trading lower after the compan...
Unlock content with
Pro Subscription
4 months ago
+11.14%
NovoCure shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $28 to $42.
